The objective of this training program is to provide post-doctoral fellows with didactic and research experience in cellular and molecular aspects of cancer to prepare them for independent investigative careers in basic and translational cancer research. The program forms the core of cancer biology training in the Helen Diller Family Comprehensive Cancer Center (CCC) at the University of California, San Francisco (UCSF). The faculty, who are all members of the CCC, consists of basic researchers, laboratory-based physician-scientists, and more applied clinician-investigators who share common interests in the multifaceted fields of cellular, molecular and structural biology applied to the understanding of mechanisms of cancer initiation, progression, diagnosis and therapy. The areas of didactic and research training will expose trainees to a spectrum of approaches, concepts and opportunities from altered gene and protein structure and expression, cancer microenvironment and immunity, cell cycling and signaling to differentiation and development. The goal of this approach is to further the understanding of cancer incidence and progression so that the trainees will have an appropriate perspective to approaching basic cancer research as well as to address, prevention, biomarkers and translation to patients. Post-doctoral trainees will join one of 34 research groups involved in studying these basic mechanisms. To broaden their experience, the trainees will have secondary mentors and will be encouraged to seek out collaborations with other research groups at UCSF or outside. Trainees will have access to all the academic resources available at UCSF. In this way, trainees will be provided with an in-depth research experience in an environment that covers the broad forefront of molecular and cellular dysregulation in cancer. Seminar programs, research-in-progress discussions and journal clubs complement the research training. Trainees must have a Ph.D. or equivalent degree in cell or molecular biology, genetics, biochemistry or an applicable discipline, or an M.D. or M.D., Ph.D. The trainees will be selected on the basis of past accomplishments and promise, course work, grades achieved, suitability for the research projects and a commitment to a research career. Trainees will receive a stipend for an average of 2 years, but will be part of the program throughout their training period of at least 3 years. The program will consist of 10 trainees, complemented by the larger group of other trainees in the host laboratories to make a significant critical mass of basic cancer researchers in the CCC. Upon completion of the program, it is anticipated that the trainees will continue careers in basic and translational cancer research in academic institutions, governmental agencies or the biotechnology industry.

Public Health Relevance

The goal of this program is to produce diverse and broadly trained scientists who will be the next generation of cancer researchers. This highly trained workforce of basic scientists and physician/scientists will be at the forefront of cancer research in the coming decades and will assume leadership roles to produce the scientific data to improve diagnosis, survival rates and quality of life of individuals with cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Anatomy/Cell Biology
Schools of Medicine
San Francisco
United States
Zip Code
Song, Ihn Young; Balmain, Allan (2015) Cellular reprogramming in skin cancer. Semin Cancer Biol 32:32-9
Affara, Nesrine I; Ruffell, Brian; Medler, Terry R et al. (2014) B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 25:809-21
Ciceri, Pietro; Müller, Susanne; O'Mahony, Alison et al. (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 10:305-12
Fouse, Shaun D; Nakamura, Jean L; James, C David et al. (2014) Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype. Neuro Oncol 16:361-71
Smith, Catherine Choy; Lasater, Elisabeth A; Lin, Kimberly C et al. (2014) Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A 111:5319-24
Asmussen, Jennifer; Lasater, Elisabeth A; Tajon, Cheryl et al. (2014) MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Cancer Discov 4:200-15
Nagarajan, Raman P; Zhang, Bo; Bell, Robert J A et al. (2014) Recurrent epimutations activate gene body promoters in primary glioblastoma. Genome Res 24:761-74
Venugopalan, Gautham; Camarillo, David B; Webster, Kevin D et al. (2014) Multicellular architecture of malignant breast epithelia influences mechanics. PLoS One 9:e101955
Ruffell, Brian; Affara, Nesrine I; Cottone, Lucia et al. (2013) Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev 27:2086-98
Chou, Jonathan; Shahi, Payam; Werb, Zena (2013) microRNA-mediated regulation of the tumor microenvironment. Cell Cycle 12:3262-71

Showing the most recent 10 out of 29 publications